medigraphic.com
Revista Médica Sinergia

2020, Number 07

<< Back Next >>

Revista Médica Sinergia 2020; 5 (07)

Dermatomyositis as a paraneoplastic syndrome

Hernández VA, Arriola ALE, Vargas GA

Language: Spanish
References: 33
Page: 1-11
PDF size: 139.08 Kb.


ABSTRACT

Inflammatory myopathies have an increased risk of malignancy, the one with the highest association being dermatomyositis. The neoplasm can be solid or hematologic. There are clinical and laboratory factors that canincrease or decrease the risk for the presentation of a myositis as a paraneoplastic disease. Among the main risk factors, the presence of anti- TIF1, anti-NXP2 and to a lesser extent anti-SAE antibodies have been observed. The main theory of its origin points to the immune response derived from the creation of mutated proteins by cancer cells. The diagnosis of malignancy can be made before, during or after the diagnosis of dermatomyositis. There is no established therapeutic regimen, however the uses of steroids, immunosuppressants or immunoglobulins have been proposed, as well as effective cancer therapy.


REFERENCES

  1. Sasaki H. Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018;28(6):913-921. https://doi.org/10.1080/14397595.2018.1467257

  2. Schmidt J. Current Classification and Management of Inflammatory Myopathies. J Neuromuscul Dis. 2018;5(2):109-129. https://doi.org/10.3233/JND-180308

  3. Thompson C, Piguet V, Choy E. The Pathogenesis of Dermatomyositis. Br J Dermatol. 2018;179(6):1233-1234. https://doi.org/10.1111/bjd.15607

  4. Jakubaszek M, Kwiatkowska B, Maślińska M. Polymyositis and dermatomyositis as a risk of developing cancer. Reumatología. 2015;53(2):101-105. https://doi.org/10.5114/reum.2015.51510

  5. Sato S, Kuwana M. Utility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting. Int J Clin Rheumatol. 2015;10(4):257-271.

  6. Findlay A, Goyal N, Mozaffar T. An Overview of Polymyositis and Dermatomyositis. Muscle Nerve. 2015;51(5):638-656. https://doi.org/10.1002/mus.24566

  7. Zerdes I, Tolia M, Nikolaou M, Tsoukalas N, Velentza L, Hajiioannou J, et al. How can we effectively address the paraneoplastic dermatomyositis: Diagnosis, risk factors and treatment options. J BUON. 2017;22(4):1073-80.

  8. Fang Y, Jan Y, Kuo C, Luo S, Yu K. Malignancy in dermatomyositis and polymyositis: analysis of 192 patients. Clin Rheumatol. 2016;35(8):1977-1984. https://doi.org/10.1007/s10067-016- 3296-8.

  9. Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, et al. Evidence supports blind screening for internal malignancy in dematomyositis: data from 2 large US dermatology cohorts. Medicine. 2018 enero: 96(3):e9639. http://dx.doi.org/10.1097/MD.0000000000009639

  10. Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol. 2017;52(1):20-33. https://doi.org/10.1007/s12016-015-8511-x

  11. Shah AA, Casciola􀇦Rosen L, Rosen A. Cancer􀇦induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol. 2015;67(2):317-326. https://doi.org/10.1002/art.3892

  12. DeWane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol. 2020;82(2):267-281. https://doi.org/10.1016/j.jaad.2019.06.1309

  13. Motomura K, Yamashita H, Yamada S, Takahashi Y, Kaneko H. Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study. Rheumatol Int. 2019;39(10),1733-1739. https://doi.org/10.1007/s00296- 019-04428-z

  14. Cassius C, Le Buanec H, Bouaziz JD, Amode R. Biomarkers in adult dermatomyositis: tools to help the diagnosis and predict the clinical outcome. J Immunol Res. 2019 Jan 14;2019:9141420. https://doi.org/10.1155/2019/9141420

  15. Uruha A, Suzuki S, Nishino I. Diagnosis of dermatomyositis: Autoantibody profile and muscle pathology. Clin Exp Neuroimmunol. 2017;8(4):302-312. https://doi.org/10.1111/cen3.12419

  16. Aussy A, Boyer O, Cordel N. Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer. Front Immunol. 2017;8:992. https://doi.org/10.3389/fimmu.2017.0099

  17. Yang WM, Chen JJ. Advances in biomarkers for dermatomyositis. Clin Chim Acta. 2018;482:172-177. https://doi.org/10.1016/j.cca.2018.03.042

  18. Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y, et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther. 2017;19(1):259. https://doi.org/10.1186/s13075-017-1469-8

  19. Aussy A, Fréret M, Gallay L, Bessis D, Vincent T, Jullien D, et al. The IgG2 Isotype of Anti– Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. Arthritis Rheumatol. 2019;71(8):1360-1370. https://doi.org/10.1002/art.40895

  20. Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositisspecific autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-644. https://doi.org/10.1097/BOR.0000000000000329

  21. Merlo G, Clapasson A, Cozzani E, Sanna L, Pesce G, Bagnasco M, et al. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets. Arch Dermatol Res. 2017;309(2):87-95. https://doi.org/10.1007/s00403-016-1704-1

  22. Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20(5):28. https://doi.org/10.1007/s11926-018-0733-5

  23. Ogawa-Momohara M, Muro Y, Mitsuma T, Katayama M, Yanaba K, Nara M, et al. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients. Clin Exp Rheumatol. 2018;36(6):990-995.

  24. Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, et al. Dermatomyositis patients with anti-nuclear matrix protein-2 autoantibodies have more edema, more severe muscle disease, and increased malignancy risk. Arthritis Care Res. 2017;69(11):1771. https://doi.org/10.1002/acr.23188

  25. Rogers A, Chung L, Li S, Casciola􀇦Rosen L, Fiorentino DF. Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res. 2017;69(12):1909-1914. https://doi.org/10.1002/acr.23210

  26. Liu Y, Xu L, Wu H, Zhao N, Tang Y, Li X, et al. Characteristics and predictors of malignancy in dermatomyositis: Analysis of 239 patients from northern China. Oncol Lett. 2018;16(5):5960- 5968. https://doi.org/10.3892/ol.2018.9409

  27. Hoesly PM, Sluzevich JC, Jambusaria-Pahlajani A, Lesser ER, Heckman MG, Abril A. Association of antinuclear antibody status with clinical features and malignancy risk in adultonset dermatomyositis. J Am Acad Dermatol. 2019;80(5):1364-1370. https://doi.org/10.1016/j.jaad.2018.11.023

  28. Selva A, Ros J, Gil A, Vila G, Trallero E, Pinal I. Malignancy and Myositis, from molecular mimicry to tumor infiltrating lymphocytes. Neuromuscul Disord. 2019;29(11):819-825. https://doi.org/10.1016/j.nmd.2019.09.014

  29. McHugh N, Tansley S. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14(5):290-302. https://doi.org/10.1038/nrrheum.2018.56

  30. Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N. Dermatomyositis: current concepts. Clin Dermatol. 2018;36(4):450-458. https://doi.org/10.1016/j.clindermatol.2018.04.003

  31. Oldroyd A, Sergeant JC, New P, McHugh NJ, Betteridge Z, Lamb JA, et al. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody– positive dermatomyositis. Rheumatology. 2019;58(4):650-655. https://doi.org/10.1093/rheumatology/key357

  32. Waldman R, DeWane ME, Lu J. Dermatomyositis: Diagnosis and treatment. J Am Acad Dermatol. 2020;82(2): 283-296. https://doi.org/10.1016/j.jaad.2019.05.105

  33. Sellami K, Mseddi M, Snoussi M, Gharbi H, Frikha F, Ben R, et al. Malignancy in a retrospective cohort of 17 patients with Dermatomyositis or Polymyositis in southern Tunisia. Rom J Intern Med. 2018;56(4):243-249. https://doi.org/10.2478/rjim-2018-0015




2020     |     www.medigraphic.com